CENTER FOR DRUG EVALUATION AND RESEARCH APPROVAL PACKAGE FOR:

APPLICATION NUMBER 21-344

Medical/Statistical Review(s)



NDA 21-344:

New Drug Application Fulvestrant (FASLODEXTM)

FDA Center for Drug Evaluation and Research
Division of Oncology Drug Products

Combined Medical/Statistical NDA Review

Medical Reviewer: Peter Bross, MD

Medical Team Leader: Grant Williams, MD

Statistical Reviewer: Peiling Yang, Ph.D

Statistical Team Leader: Gang Chen, Ph.D



CLINICAL REVIEW

Table of Contents


1.		Executive Summary5			
	a.	Reco	nmendations5		
		i.	Recommendation on Approvability	5	
		ii.	Recommendation on Phase 4 Studies and/or Risk Management Steps	5	
	b.	Summary of Clinical Findings6			
		i.	Brief Overview of Clinical Program	(
		ii.	Efficacy		
		iii.	Safety		
		iv.	Dosing		
		v.	Special Populations		
2.		Clinical Review			
	a.	Introduction and Background9			
		i.	Drug Established and Proposed Trade Name, Drug Class, Applicant's Proposed Indication(s), Dose, Regimens, Age Groups	Ç	
		ii.	Drug Chemical Structure	10	
		iii.	State of Armamentarium for Indication(s)	10	
	b.	o. Important Milestones in Product Development			
	c.	Important Issues with Pharmacologically Related Agents			
	d.	Clinically Relevant Findings From Chemistry, Animal Pharmacology and Toxicology, Microbiology, Biopharmaceutics, Statistics and/or Other Consultant Reviews			
		i.	Pharmacology/Toxicology	18	
	e.	Hun	nan Pharmacokinetics and Pharmacodynamics	 2 1	
		i.	Pharmacokinetics	2	



Page 2

CLINICAL REVIEW

		ii.	Pharmacodynamics	23
	f.	IV. I	Description of Clinical Data and Sources	29
		i.	Overall Data	29
		ii.	Tables Listing the Clinical Trials	29
		iii.	Literature Review	33
	g.	Clin	ical Review Methods	34
		i.	How the Review was Conducted	34
		ii.	Overview of Materials Consulted in Review	34
		iii.	Overview of Methods Used to Evaluate Data Quality and Integrity	34
		iv.	Were Trials Conducted in Accordance with Accepted Ethical Standard	ds 35
		v.	Evaluation of Financial Disclosure	35
3.		Inte	egrated Review of Efficacy	36
	a.	Brie	f Statement of Conclusions	36
	b.	Gen	eral Approach to Review of the Efficacy of the Drug	37
		i.	Phase 2 studies of efficacy	37
		ii.	Phase 3 studies reviewed in detail	38
		iii.	Ongoing studies in first line indication	39
	c.	Deta	ailed Review of Trials by Indication	39
		i.	Proposed indication	39
		ii.	Overview of the clinical trial program	40
		iii.	Phase 3 clinical trials	41
		iv.	Efficacy assessments	45
		v.	Statistical plan	49
		vi.	Study conduct	52
		vii.	Combined Results of Randomized Trials	55



CLINICAL REVIEW

	viii.	Efficacy results by trial: Trial #20 (European open label)	60			
	ix.	Efficacy results by trial: Trial #21 (North American - double blind dou dummy)				
	х.	Preliminary Results of trial #0025 in first line indication	85			
	xi.	Overall Efficacy Conclusions	87			
d.	Integrated Review of Safety					
	i.	Brief Statement of Conclusions	90			
	ii.	Description of Patient Exposure	90			
	iii.	Methods and Specific Findings of Safety Review	92			
	iv.	Adequacy of Safety Testing	96			
	v.	Summary of Critical Safety Findings and Limitations of Data	97			
e.	Dosi	ng, Regimen, and Administration Issues	97			
f.	Use i	n Special Populations	98			
	i	Evaluation of Applicant's Gender Effects Analyses and Adequacy of Investigation	98			
	ii.	Evaluation of Evidence for Age, Race, or Ethnicity Effects on Safety of Efficacy				
	iii.	Evaluation of Pediatric Program	98			
	iv.	Comments on Data Available or Needed in Other Populations	99			
g.	Conc	Conclusions and Recommendations				
	i.	Conclusions	9 9			
	ii.	Dosing	. 100			
	iii.	Tradename issues	. 100			
	iv	Recommendations	100			

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

